Conv. Plasma
Nigella Sativa

All HCQ studies
Meta analysis
study COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization 3% Improvement Relative Risk HCQ for COVID-19  Gianfrancesco et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 600 patients in multiple countries No significant difference in hospitalization Gianfrancesco et al., Annals of the Rh.., May 2020 Favors HCQ Favors control

Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry

Gianfrancesco et al., Annals of the Rheumatic Diseases, 79:7, 859-866, doi:10.1136/annrheumdis-2020-217871
May 2020  
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Analysis of rheumatic disease patients showing no significant association between antimalarial therapy and hospitalisation, OR=0.94 [0.57-1.57], p=0.82 after adjustments.
This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the baseline risk differences within systemic autoimmune patients.
risk of hospitalization, 3.3% lower, RR 0.97, p = 0.82, treatment 58 of 130 (44.6%), control 219 of 470 (46.6%), NNT 50, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Gianfrancesco et al., 28 May 2020, retrospective, database analysis, multiple countries, peer-reviewed, 28 authors.
This PaperHCQAll
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely, Loreto Carmona, Maria I Danila, Laure Gossec, Zara Izadi, Lindsay Jacobsohn, Patricia Katz, Saskia Lawson-Tovey, Elsa F Mateus, Stephanie Rush, Gabriela Schmajuk, Julia Simard, Anja Strangfeld, Laura Trupin, Katherine D Wysham, Suleman Bhana, Wendy Costello, Rebecca Grainger, Jonathan S Hausmann, Jean W Liew, Emily Sirotich, Paul Sufka, Zachary S Wallace, Jinoos Yazdany, Pedro M Machado, Dr Philip C Robinson
Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217871
Objectives COViD-19 outcomes in people with rheumatic diseases remain poorly understood. The aim was to examine demographic and clinical factors associated with COViD-19 hospitalisation status in people with rheumatic disease. Methods Case series of individuals with rheumatic disease and COViD-19 from the COViD-19 Global Rheumatology alliance registry: 24 March 2020 to 20 april 2020. Multivariable logistic regression was used to estimate ORs and 95% Cis of hospitalisation. age, sex, smoking status, rheumatic disease diagnosis, comorbidities and rheumatic disease medications taken immediately prior to infection were analysed. results a total of 600 cases from 40 countries were included. nearly half of the cases were hospitalised (277, 46%) and 55 (9%) died. in multivariableadjusted models, prednisone dose ≥10 mg/day was associated with higher odds of hospitalisation (OR 2.05, 95% Ci 1.06 to 3.96). Use of conventional disease-modifying antirheumatic drug (DMaRD) alone or in combination with biologics/Janus Kinase inhibitors was not associated with hospitalisation (OR 1.23, 95% Ci 0.70 to 2.17 and OR 0.74, 95% Ci 0.37 to 1.46, respectively). non-steroidal antiinflammatory drug (nsaiD) use was not associated with hospitalisation status (OR 0.64, 95% Ci 0.39 to 1.06). Tumour necrosis factor inhibitor (anti-TnF) use was associated with a reduced odds of hospitalisation (OR 0.40, 95% Ci 0.19 to 0.81), while no association with antimalarial use (OR 0.94, 95% Ci 0.57 to 1.57) was observed. Conclusions We found that glucocorticoid exposure of ≥10 mg/day is associated with a higher odds of hospitalisation and anti-TnF with a decreased odds of hospitalisation in patients with rheumatic disease. neither exposure to DMaRDs nor nsaiDs were associated with increased odds of hospitalisation. InTrOduCTIOn The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus is of particular concern for people with rheumatic disease or those who are immunosuppressed. Whether having a rheumatic disease or receiving immunosuppressive treatment is associated with severe infection and subsequent poor outcomes is unknown. In general, immunosuppression and the presence of comorbidities are associated with an increased risk of serious infection in people with Key messages What is already known about this subject? ► Data regarding outcomes for people with rheumatological disease and COVID-19 remain scarce and limited to small case series. ► Due to underlying immune system dysfunction and the common use of immunosuppressants, there is concern about poorer outcomes in this population and uncertainty about medication management during the pandemic. What does this study add? ► Moderate to high dose glucocorticoids were associated with a higher risk of hospitalisation for COVID-19. ► Biologic therapies, NSAIDs and antimalarial drugs like hydroxychloroquine were not associated with a higher risk of hospitalisation for COVID-19. How might..
Arentz, Yim E, Klaff L, Characteristics and outcomes of 21 critically ill patients with COViD-19 in Washington state, JAMA, doi:10.1001/jama.2020.4326
Borba, Val, Vs, Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (saRs-CoV-2) infection: preliminary safety results of a randomized, double-blinded, phase iib clinical trial
Chen, Hu, Zhang, efficacy of hydroxychloroquine in patients with COViD-19: results of a randomized clinical trial, MedRxiv
Chen, Liu, a pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COViD-19
Chen, Wu, Chen, Clinical characteristics of 113 deceased patients with coronavirus disease, BMJ, doi:10.1136/bmj.m1091
Day, Covid-19: european drugs agency to review safety of ibuprofen, BMJ, doi:10.1136/bmj.m1168
Favalli, Caporali, incidence and clinical course of COViD-19 in patients with connective tissue diseases: a descriptive observational analysis, J Rheumatol, doi:10.3899/jrheum.200507
Favalli, Cimaz, What is the true incidence of COViD-19 in patients with rheumatic diseases?, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217615
Feldmann, Rn, Jn, Trials of anti-tumour necrosis factor therapy for COViD-19 are urgently needed, The Lancet, doi:10.1016/S0140-6736(20)30858-8
Gautret, Lagier, Parola, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COViD-19 patients with at least a six-day follow up: an observational study, Travel Med Infect Dis
Gautret, Parola, Hydroxychloroquine and azithromycin as a treatment of COViD-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Gianfrancesco, Kl, Gossec L, Rheumatic disease and COViD-19: initial data from the COViD-19 global rheumatology alliance provider registry, Lancet Rheumatol
Goyal, Choi, Pinheiro, Clinical characteristics of Covid-19 in new York City, N Engl J Med Overseas Ed, doi:10.1056/NEJMc2010419
Graef Er, Liew, Ms, Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217480
Grasselli, Zangrillo A, Zanella A, Baseline characteristics and outcomes of 1591 patients infected with saRs-CoV-2 admitted to iCUs of the lombardy region, italy, JAMA, doi:10.1001/jama.2020.5394
Guan, Zy N, Hu, Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Huang, Wang, Li, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet, doi:10.1016/S0140-6736(20)30183-5
Kim Ahj, Sparks, Liew, a rush to judgment? rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COViD-19, Ann Intern Med, doi:10.7326/M20-1223
Konig, Scheetz, Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude saRs-CoV-2 infection and severe COViD-19
Listing, Gerhold, Zink, The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment, Rheumatology, doi:10.1093/rheumatology/kes305
Luo, Liu, Qiu L, Tocilizumab treatment in COViD-19: a single center experience, J Med Virol, doi:10.1002/jmv.25801
Magagnoli, Pereira, Outcomes of hydroxychloroquine usage in United states veterans hospitalized with Covid-19, medRxiv
Mahevas, Tran, Roumier, evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COViD-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv
Mathian A, Mahevas, Rohmer, Clinical course of coronavirus disease 2019 (COViD-19) in a series of 17 patients with systemic lupus erythematosus under longterm treatment with hydroxychloroquine, Ann Rheum Dis
Mehta, Mcauley, Brown, COViD-19: consider cytokine storm syndromes and immunosuppression, Lancet, doi:10.1016/S0140-6736(20)30628-0
Mikuls, Johnson Sr, Fraenkel L, american College of rheumatology guidance for the management of adult patients with rheumatic disease during the COViD-19 pandemic, Arthritis Rheumatol, doi:10.1002/art.41301
Monti S, Balduzzi S, Delvino, Clinical course of COViD-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies, Ann Rheum Dis
Richardson S, Js, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COViD-19 in the new York City area, JAMA, doi:10.1001/jama.2020.6775
Rmb, Machado, Kroon, eUlaR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of saRs-CoV-2, Ann Rheum Dis
Robinson, Yazdany, The COViD-19 global rheumatology alliance: collecting data in a pandemic, Nat Rev Rheumatol, doi:10.1038/s41584-020-0418-0
Ruan, Yang, Wang, Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TnF inhibition and what does this imply for the individual patient?, Intensive Care Med, doi:10.1136/ard.2011.151043
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COViD-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention, JAMA
Xu, Han, Li, effective treatment of severe COViD-19 patients with tocilizumab, ChinaXiv
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COViD-19 in Wuhan, China: a retrospective cohort study, Lancet, doi:10.1016/S0140-6736(20)30566-3
Zs, Bhana S, Js, The rheumatology community responds to the COViD-19 pandemic: the establishment of the COViD-19 global rheumatology alliance, Rheumatology, doi:10.1093/rheumatology/keaa191
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop